{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:04:42Z","timestamp":1749787482086,"version":"3.41.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Gaucher Disease (GD) is a lysosomal storage disorder. Mutations in the GBA1 gene cause glucocerebrosidase enzyme deficiency that leads to the accumulation of its substrates. Enzyme replacement therapy emerged as a natural history-changing treatment. Up to now, mainly measurable treatment targets have been investigated for patients. In this study, the number of real-life based and GD related events before and after ERT were evaluated for the first time to assess the impact of ERT on GD patients in real-life settings. The events investigated consist of hematopoietic, musculoskeletal, gastrointestinal, neurologic, respiratory system and growth and puberty-related events, as well as events related to routine daily activities, and malignancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 29 events were reported from 5 different group of events between \u2212\u200912 to -6 months and 16 events from \u2212\u20096 months to baseline in all patients. After the initiation of ERT, the number of new events decreased to 1 in 6\u201312 months. At the end of the follow-up period, between 30 and 36 months, only 1 new event was recorded, the minimum event number overall. For all groups of events, there was a trend to decrease of the events for overall follow-up period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In conclusion, this is the first study that evaluate event-based outcomes in GD patients receiving ERT and show the real-life data by evaluating not only laboratory parameters but also clinical consequences of the treatment, providing practical clinical follow up.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03690-8","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T09:07:28Z","timestamp":1749719248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Event-based real-life outcomes of patients with non-neuronopathic Gaucher disease receiving ert"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0647-3138","authenticated-orcid":false,"given":"Ay\u015fe","family":"Aky\u00fcz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asl\u0131","family":"\u0130nci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lyas","family":"Okur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"T\u00fcmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih S\u00fcheyl","family":"Ezg\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"3690_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska KS, LaMarca ME, Scott CR, Sidransky E. Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat S. 2008;29:567\u201383.","journal-title":"Hum Mutat S"},{"issue":"6","key":"3690_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jbmr.3734","volume":"34","author":"D Hughes","year":"2019","unstructured":"Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, Kindmark A, Mistry P, Poll L, Weinreb N, Deegan P. Gaucher disease in bone: from pathophysiology to practice. J Bone Min Res. 2019;34(6):996\u20131013.","journal-title":"J Bone Min Res"},{"issue":"2","key":"3690_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","volume":"132","author":"EC Daykin","year":"2021","unstructured":"Daykin EC, Ryan E, Sidransky E. Diagnosing neuronopathic gaucher disease: new considerations and challenges in assigning gaucher phenotypes. Mol Genet Metab. 2021;132(2):49\u201358. https:\/\/doi.org\/10.1016\/j.ymgme.2021.01.002","journal-title":"Mol Genet Metab"},{"key":"3690_CR4","doi-asserted-by":"crossref","unstructured":"Stirnemann J et al. The French Gaucher\u2019s disease registry: clinical characteristics,complications and treatment of 562 patients. Orphanet J. Rare Dis., s. 2012;7:77.","DOI":"10.1186\/1750-1172-7-77"},{"key":"3690_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"s 18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;s 18:441.","journal-title":"Int J Mol Sci"},{"key":"3690_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ajh.24801","volume":"929","author":"PK Mistry","year":"2017","unstructured":"Mistry PK, et al. Transformation in pretreatment manifestations of gaucher disease type 1 during two decades of Alglucerase\/imiglucerase enzyme replacement therapy in the international collaborative gaucher group (ICGG) gaucher registry. Am J Hematol. 2017;929:929\u201339.","journal-title":"Am J Hematol"},{"key":"3690_CR7","doi-asserted-by":"crossref","unstructured":"Weinreb NJ et al. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. 2021, Molecular Genetics and Metabolism, s. 132,100\u2013111.","DOI":"10.1016\/j.ymgme.2020.12.295"},{"issue":"Suppl 10 1","key":"3690_CR8","first-page":"72","volume":"12","author":"HN Baris","year":"2014","unstructured":"Baris HN, Cohen IJ, Mistry PK. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. Pediatr Endocrinol Rev. 2014;12(Suppl 10 1):72\u201381.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"12","key":"3690_CR9","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/17512433.2018.1549486","volume":"11","author":"P Gupta","year":"2018","unstructured":"Gupta P, Pastores G. Pharmacological treatment of pediatric gaucher disease. Expert Rev Clin Pharmacol. 2018;11(12):1183\u201394. https:\/\/doi.org\/10.1080\/17512433.2018.1549486","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3690_CR10","unstructured":"Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Pl\u00f6ckinger U, Rosenbaum H. S management goals for type 1 gaucher disease: an expert consensus document from the European working group on gaucher disease. Blood Cells, Molecules and Diseases. 2016."},{"key":"3690_CR11","doi-asserted-by":"crossref","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. 2007, Ann Intern Med., s. Jan 16;146(2):77\u201386.","DOI":"10.7326\/0003-4819-146-2-200701160-00148"},{"key":"3690_CR12","first-page":"3085","volume":"91","author":"D Krasnewich","year":"1998","unstructured":"Krasnewich D, Dietrich K, Bauer L, Ginns EI, Sidransky E, Hill S. Splenectomy in gaucher disease: new management dilemmas. Blood S. 1998;91:3085\u20137.","journal-title":"Blood S"},{"issue":"23","key":"3690_CR13","first-page":"6920","volume":"24","author":"S Linari","year":"2022","unstructured":"Linari S, Castaman G. Hemostatic abnormalities in gaucher disease: mechanisms and clinical implications. J Clin Med S Nov. 2022;24(23):6920.","journal-title":"J Clin Med S Nov"},{"key":"3690_CR14","doi-asserted-by":"crossref","unstructured":"Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szyma\u0144ska A. Therapeutic Goals in the Treatment of Gaucher Disease. 2004 Oct., Semin Hematol., s. 41;4\u201314.","DOI":"10.1053\/j.seminhematol.2004.07.009"},{"key":"3690_CR15","doi-asserted-by":"crossref","unstructured":"Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS. Zimran A.1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. 2002, Am J Med, s. 113:112\u2013119.","DOI":"10.1016\/S0002-9343(02)01150-6"},{"key":"3690_CR16","doi-asserted-by":"crossref","unstructured":"Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: A review. 2002, J Radiol, s. 75:A2-A12.","DOI":"10.1259\/bjr.75.suppl_1.750002"},{"key":"3690_CR17","doi-asserted-by":"crossref","unstructured":"Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, Kindmark A, Mistry P, Poll L, Weinreb N, Deegan P. Gaucher Disease in Bone: From Pathophysiology to Practice. 2019, J Bone Miner Res., s. 2019;34(6):996\u20131013.","DOI":"10.1002\/jbmr.3734"},{"key":"3690_CR18","doi-asserted-by":"crossref","unstructured":"Cappellini MD, Carubbi F, Di Rocco M, Giona F, Giuffrida G. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. 2023, Blood Cells Mol Dis, s. Jan;98:102705.","DOI":"10.1016\/j.bcmd.2022.102705"},{"key":"3690_CR19","doi-asserted-by":"crossref","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. 2000, Arch Intern Med, s. 160:2835\u20132843.","DOI":"10.1001\/archinte.160.18.2835"},{"key":"3690_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1096-7192(02)00122-1","volume":"77","author":"PK Mistry","year":"2002","unstructured":"Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, Meeker DP, Goldman ME. Pulmonary hypertension in type 1 Gaucher\u2019s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab S. 2002;77:91\u20138.","journal-title":"Mol Genet Metab S"},{"key":"3690_CR21","doi-asserted-by":"crossref","unstructured":"Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: Dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. 1993, Blood, s. 82:408\u20134016.","DOI":"10.1182\/blood.V82.2.408.bloodjournal822408"},{"key":"3690_CR22","doi-asserted-by":"crossref","unstructured":"Huang YN, Huang JY, Liao WL, Chiang SL, Liu KW, Bau DT, Wang CH, Su PH. Incidence of Pulmonary and Respiratory Conditions in Gaucher Disease from 2000 to 2020: A Multi-institutional Cohort Study. 2023, In Vivo, s. Sep-Oct;37(5):2276\u20132283.","DOI":"10.21873\/invivo.13330"},{"key":"3690_CR23","doi-asserted-by":"crossref","unstructured":"Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, Gribble TJ, Wappner RS, Wisch JS, Weinreb NJ. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. 1996, J Pediatr, s. 129:149\u2013\u200953.","DOI":"10.1016\/S0022-3476(96)70203-2"},{"key":"3690_CR24","doi-asserted-by":"crossref","unstructured":"Ida H, Rennert OM, Kobayashi M, Eto Y. Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease2001, Eur J Pediatr, s. 160:21\u201325.","DOI":"10.1007\/PL00008411"},{"key":"3690_CR25","unstructured":"Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, Phillip M, Yaniv Y, Cohen IJ. Delayed growth and puberty in patients with Gaucher disease type 1: Natural history and effect of splenectomy and\/or enzyme replacement therapy. 2000, Isr Med Assoc J, s. 2:158\u2013163."},{"key":"3690_CR26","doi-asserted-by":"crossref","unstructured":"Oliveira FL, Alegra T, Dornelles A, Krug BC, Netto CB, da Rocha NS, Picon PD, Schwartz IV. Quality of life of brazilian patients with Gaucher disease and fabry disease. 2013, JIMD Rep., s. 3;7:31\u2013\u20097.","DOI":"10.1007\/8904_2012_136"},{"issue":"5","key":"3690_CR27","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/jimd.12382","volume":"44","author":"Y Cohen","year":"2021","unstructured":"Cohen Y, Frydman D, Rotem R, Kofman R, Zimran A, Revel-Vilk S, Grisaru-Granovsky S. Risk of postpartum hemorrhage in multiparous women with gaucher disease: A call for reconsidering enzyme replacement therapy in all pregnant patients. J Inherit Metab Dis. 2021;44(5):1165\u2013117.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03690-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03690-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03690-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T09:07:37Z","timestamp":1749719257000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03690-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3690"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03690-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was obtained from Gazi University, decision number is 04.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individuals included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors confirm that they had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All of the authors gave final approval of this version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article. On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"302"}}